Results 101 to 110 of about 3,304 (220)

Six-month results from a Phase III randomized trial of fixed-combination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension

open access: yesClinical Ophthalmology, 2013
Jess T Whitson,1 Tony Realini,2 Quang H Nguyen,3 Matthew G McMenemy,4 Stephen M Goode5 1University of Texas Southwestern Medical Center at Dallas, Dallas, TX, 2West Virginia University Eye Institute, Morgantown, WV, 3Scripps Clinic, La Jolla, CA, 4Lone ...
Whitson JT   +4 more
doaj  

Estudio galénico de los medicamentos utilizados en España para el tratamiento del Glaucoma [PDF]

open access: yes, 2018
La presión intraocular elevada es el principal factor de riesgo implicado en el desarrollo del glaucoma, segunda causa de ceguera irreversible a nivel mundial según la OMS.
Lafita Llorca, Carlos Javier
core  

Patent Clutter [PDF]

open access: yes, 2018
Patent claims are supposed to clearly and succinctly describe the patented invention, and only the patented invention. This Article hypothesizes that a substantial amount of language in patent claims is in fact not about the core invention, which may ...
Freilich, Janet
core   +1 more source

Brinzolamide-timolol suspension: acceptability and side effect profile

open access: yesClinical Ophthalmology, 2011
MD Doherty, SG Fraser, PS PhelanSunderland Eye Infirmary, Sunderland, Tyne and Wear, UKBackground: This study aimed to determine the frequency, nature, and impact of side effects associated with the use of brinzolamide-timolol suspension, a topical ...
Doherty MD, Fraser SG, Phelan PS
doaj  

Twenty-four hour efficacy of glaucoma medications [PDF]

open access: yes, 2015
Katsanos, Andreas   +5 more
core   +1 more source

The impact of fish oil fatty-acids on post-prandial vascular reactivity. [PDF]

open access: yes, 2014
Progressive loss of vascular reactivity and increased vascular tone with age are being increasingly recognised as significant cardiovascular disease (CVD) risk factors.
Mcmanus, Sean
core  

Farmacoterapia actual para el tratamiento de Glaucoma Primario de Ángulo Abierto: Revisión de la Literatura [PDF]

open access: yes, 2013
Uno de los mayores problemas de salud en el mundo es la incapacidad física secundaria a la pérdida de la visión en individuos. Estando entre las tres principales causas de ceguera todas las causas de glaucoma (de ángulo cerrado, abierto, primario y ...
Jaimes García, Javier   +1 more
core  

Bilateral Choroidal Detachment Induced by Unilateral Application of a Fixed Combination of Topical Timolol Maleate and Brinzolamide [PDF]

open access: yes, 2016
We describe a 66-year-old man who developed bilateral choroidal detachment that was induced by unilateral topical administration of a fixed combination of 1% brinzolamide and 0.5% timolol maleate the day after an uneventful phacoemulsification surgery ...
DONMEZ, Oya   +3 more
core   +1 more source

Clinical effectiveness of brinzolamide 1%–brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension

open access: yesClinical Ophthalmology, 2015
Sourabh Sharma,1 Sameer Trikha,1 Shamira A Perera,1 Tin Aung1,2 1Glaucoma Department, Singapore Eye Research Institute, Singapore National Eye Centre, 2Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore ...
Sharma S, Trikha S, Perera SA, Aung T
doaj  

Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus

open access: yesPatient Preference and Adherence, 2014
Quang H Nguyen Division of Ophthalmology, Scripps Clinic, La Jolla, CA, USA Abstract: Glaucoma is one of the leading causes of blindness and is characterized by optic nerve damage that results in visual field loss.
Nguyen QH
doaj  

Home - About - Disclaimer - Privacy